Breadcrumb

Breadcrumbs

  • Home
  • Media
  • Press Releases

MEDIA_REFRESH_DATA_PRESS_RELEASE

Media

U.S. News Room

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

September 19, 2021 NEW Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations Download press releaseDownload
September 18, 2021 NEW ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer Download press releaseDownload
September 18, 2021 NEW ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer Download press releaseDownload
September 17, 2021 NEW DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers Download press releaseDownload
September 17, 2021 NEW ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial Download press releaseDownload
September 16, 2021 NEW DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric Cancer Download press releaseDownload
September 07, 2021 NEW Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress Download press releaseDownload
August 09, 2021 ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer Download press releaseDownload
July 08, 2021 DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric Cancer Download press releaseDownload
June 14, 2021 DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer Download press releaseDownload
Search keyword not provided, please provide search keyword.
Showing 1 - 10 of 202 results.